11/17/2025
What does it take to turn a decades-old idea into a $14 Billion acquisition?
Dr. Steven Paul’s story is a blueprint that we are delving into at the “Breakthrough Biotech Builders Series”. From leading Lilly Research Laboratories for 17 years at Eli Lilly and Company and overseeing the development of CNS blockbusters like Zyprexa and Cymbalta, Steve Paul didn't just manage R&D—he shaped the entire drug discovery landscape.
Dr. Steve helped identify the potential of the psychiatric drug xanomeline decades ago. Later, he returned to the compound as CEO of Karuna Therapeutics to spearhead its development, eventually culminating in its acquisition by Bristol Myers Squibbfor $14B.
This is the kind of unparalleled insight you'll gain in our inaugural session of “Breakthrough Biotech Builders Series”. This Series is designed to accelerate the translation of groundbreaking ideas into vital medicines —a unique platform for biotech founders & CEOs to learn from and connect with a true pantheon of influential figures in the Biotech and Pharma sectors.
Join the Inaugural fireside chat:
Date: Wed, Nov 19th, 2025
Location: The Kendall Hotel, Cambridge, MA
RSVP: https://luma.com/5rfgvqfd
Featured guest speaker: Dr. Steve Paul (Former CEO/President of Karuna Therapeutics, Co-founder of Sage Therapeutics and Voyager Therapeutics, Inc., Former President of Lilly Research Laboratories).
Moderator: Prof. William Chin (Bill), former Pharma R&D leader at Eli Lilly and Bertarelli Professor Emeritus at Harvard Medical School.
The Breakthrough Biotech Builders series is organized by the TINS: Technology Innovation Studio, and the first session is graciously sponsored by Greenberg Traurig, LLP. Special thanks to Andrew (A.J.) Tibbetts & Prashant Girinath for their support.
